Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

October 11, 2006 08:00 ET

CV Technologies; Maker of COLD-fX'TM'-Issues Update on U.S. Launch

EDMONTON, ALBERTA--(CCNMatthews - Oct. 11, 2006) -

This release is not for distribution over U.S. Newswire Services

CV Technologies Inc. (TSX:CVQ) - maker of COLD-fX™ - today provided an update to the business, scientific and investment communities.

U.S. Launch of COLD-fX

- COLD-fX is being officially launched in the United States today and will be distributed by most of the leading pharmacy chains in the U.S. in their cough and cold section.

- Hockey legend and COLD-fX celebrity spokesman Mark Messier, and CV Technologies' President and CEO & Chief Scientific Officer, Dr. Jacqueline Shan, will be part of a public awareness campaign this week which will include TV, radio, newspaper and magazine interviews.

- The U.S. marketing campaign involves advertising in leading newspapers and radio stations in major metropolitan centres along with promotions with the National Hockey League® under a new partnership with the league and its players association.

- Included in pre-launch activities were national advertisements in USA Today and sponsorship of the 2006-2007 NHL season launch party in New York.

Medical, Industry Publications and Initiatives

- COLD-fX will be included in the 2007 issue of the Physicians Desk Reference, used by a majority of the 800,000 American doctors and commonly found in hospitals and pharmacies in the U.S. Specific information on COLD-fX has already been directly mailed to pharmacists and physicians as an addendum to the 2007 companion book: Physicians Desk Reference for Nonprescription Drugs, Dietary Supplements and Herbs. This publication references the supporting clinical trials and scientific research on COLD-fX and will assist greatly in creating awareness among medical professionals.

- The Company is exploring opportunities to conduct research collaborations with leading U.S. medical organizations as part of the campaign to further generate support and COLD-fX awareness in the health care community.

About CV Technologies Inc.

CV Technologies, founded in 1992, is a global leader in the development and commercialization of naturally derived, evidence based, clinically tested medicines for disease prevention and health maintenance. The Company's lead product - COLD-fX™ - the top selling cold and flu remedy in Canada according to ACNielsen (52 weeks ending January 21, 2006), strengthens the immune system and is widely used as a leading over the counter remedy (OTC) for preventing and relieving cold and flu infections. In the U.S. it is marketed as an immune enhancing dietary supplement. COLD-fX™ , with its unique and patented mechanism of action was standardized according to the Company's ChemBioPrint (CBP) Process. The CBP process precisely identifies the chemical profile and biological activity of multi-active compounds in evidence-based natural therapeutics. The CBP process also provides a manufacturing protocol that ensures each batch of the final product delivers verifiable and provable health benefits. All international patents and trademarks are held by fX LifeSciences International GmbH. COLD-fX™ is distributed and sold in the U.S. by COLD-fX Pharmaceuticals (USA) Inc. Both companies are wholly-owned subsidiaries of CV Technologies.

This news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results or events to differ materially from the results or events predicted in this discussion, including those comments predicting the timing and/or initiation of clinical trials, clinical trial results and associated regulatory clearances, entry and timing of entry into the U.S. market and the potential success of such initiatives. Factors which could cause actual results or events to differ include, but are not limited to: the impact of competition; consumer confidence and spending levels; general economic conditions; interest and currency exchange rates; unseasonable weather patterns; the cost and availability of capital; the cost and availability of grants/funding; product development and the risk that clinical trials may not demonstrate the safety and efficacy required to satisfy the regulatory authorities. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct and that the results, performance or achievements expressed in, or implied by, forward-looking statements within this disclosure will occur, or if they do, that any benefits may be derived from them. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company assumes no duty to update this disclosure.

Contact Information